Yusuke Higuchi
Overview
Explore the profile of Yusuke Higuchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
990
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Urano E, Itoh Y, Suzuki T, Sasaki T, Kishikawa J, Akamatsu K, et al.
Sci Transl Med
. 2023 Aug;
15(711):eadi2623.
PMID: 37647387
The Omicron variant continuously evolves under the humoral immune pressure exerted by vaccination and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and the resulting Omicron subvariants display further immune...
12.
Poku E, Ono M, Higuchi Y, Chea J, Melendez E, Teo J, et al.
Curr Mol Pharmacol
. 2023 Aug;
17(1):e170823219875.
PMID: 37594155
Introduction: Our previous work has demonstrated significant effects on the oxidative stress response, mitochondrial function, and oxidative phosphorylation in the livers and intestines of p300 S89A knockin (S89AKI) mice. We...
13.
Moriyama S, Anraku Y, Taminishi S, Adachi Y, Kuroda D, Kita S, et al.
Nat Commun
. 2023 Jul;
14(1):4198.
PMID: 37452031
SARS-CoV-2 Omicron subvariants have evolved to evade receptor-binding site (RBS) antibodies that exist in diverse individuals as public antibody clones. We rationally selected RBS antibodies resilient to mutations in emerging...
14.
Minami Y, Hoshino A, Higuchi Y, Hamaguchi M, Kaneko Y, Kirita Y, et al.
Nat Commun
. 2023 Jul;
14(1):4084.
PMID: 37443159
Nonalcoholic steatohepatitis (NASH) is a progressive disorder with aberrant lipid accumulation and subsequent inflammatory and profibrotic response. Therapeutic efforts at lipid reduction via increasing cytoplasmic lipolysis unfortunately worsens hepatitis due...
15.
Shichijo T, Tatetsu H, Nosaka K, Higuchi Y, Kikukawa Y, Toyoda K, et al.
Leuk Lymphoma
. 2023 Jun;
64(10):1706-1710.
PMID: 37386917
No abstract available.
16.
Tatetsu H, Higuchi Y, Shichijo T, Oda K, Nakata H, Yasunaga J, et al.
Int J Hematol
. 2023 Jun;
118(2):303-305.
PMID: 37380921
No abstract available.
17.
Kasahara T, Ogata T, Nakanishi N, Tomita S, Higuchi Y, Maruyama N, et al.
Heliyon
. 2023 Jun;
9(6):e17193.
PMID: 37360100
Pulmonary hypertension (PH) is associated with a poor prognosis even in recent years. Caveolin-1 (CAV1), a caveolae-associated protein, is a causal gene in PH. Cavin-2, one of the other caveolae-associated...
18.
Higuchi Y, Nguyen C, Chimge N, Ouyang C, Teo J, Kahn M
Curr Mol Pharmacol
. 2023 May;
17(1):e290523217409.
PMID: 37254542
Background And Objective: The first clinically evaluated CBP/β-catenin antagonist, PRI-724, displayed an excellent safety profile administered intravenously via continuous infusion. Eisai recently disclosed a third-generation, orally available, reportedly CBP/β-catenin antagonist,...
19.
Havranek B, Lindsey G, Higuchi Y, Itoh Y, Suzuki T, Okamoto T, et al.
Commun Biol
. 2023 May;
6(1):513.
PMID: 37173421
SARS-CoV-2, especially B.1.1.529/omicron and its sublineages, continues to mutate to evade monoclonal antibodies and antibodies elicited by vaccination. Affinity-enhanced soluble ACE2 (sACE2) is an alternative strategy that works by binding...
20.
Andlovic B, Heilmann G, Ninck S, Andrei S, Centorrino F, Higuchi Y, et al.
Cell Chem Biol
. 2023 May;
30(6):573-590.e6.
PMID: 37130519
The natural product family of the fusicoccanes (FCs) has been shown to display anti-cancer activity, especially when combined with established therapeutic agents. FCs stabilize 14-3-3 protein-protein interactions (PPIs). Here, we...